<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526513</url>
  </required_header>
  <id_info>
    <org_study_id>APIDR_L_01913</org_study_id>
    <nct_id>NCT00526513</nct_id>
  </id_info>
  <brief_title>Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 &amp; 2 Diabetes Mellitus</brief_title>
  <acronym>SCALE</acronym>
  <official_title>Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 &amp; 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      To determine the effect of insulin glulisine on glycemic control (HbA1c, FBG &amp; PPBG) from&#xD;
      baseline to the end of the study.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To evaluate the safety of insulin glulisine in basal/bolus regimen by monitoring the&#xD;
      incidence of hypoglycemia and other adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated Haemoglobin (HbA1c)</measure>
    <time_frame>At 3 months after the treatment start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycosylated Haemoglobin (HbA1c)</measure>
    <time_frame>At 6 months after the treatment start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Control of Fasting Blood Glucose (FBG)</measure>
    <time_frame>At 3 months after the treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of Post-Prandial Glycemia (PPBG)</measure>
    <time_frame>At 3 months after the treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of Post-Prandial Glycemia (PPBG)</measure>
    <time_frame>At 6 months after the treatment start</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">188</enrollment>
  <condition>Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine</intervention_name>
    <description>subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 1 or type 2 diabetes mellitus previously treated for 6 months with&#xD;
             prandial insulin + Basal insulin or Premix (Type I) or by either a basal insulin + OAD&#xD;
             or basal + RHI/other short acting analogue insulin or Premix (Type II) with HbA1c &gt;7%.&#xD;
&#xD;
          -  Adequate hepatic and renal functions&#xD;
&#xD;
          -  Ability and willingness of a tight antidiabetic therapy and to perform blood glucose&#xD;
             self-monitoring and especially blood glucose profiles, using a blood glucometer at&#xD;
             home.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women or women of childbearing potential not using adequate&#xD;
             contraception.&#xD;
&#xD;
          -  Patients with hypersensitivity to insulin glulisine or to any of the excipients.&#xD;
&#xD;
          -  History of diabetic ketoacidosis.&#xD;
&#xD;
          -  Diabetic retinopathy with surgical treatment (laser photocoagulation or vitrectomy) in&#xD;
             the 3 months prior to study entry or which may require surgical treatment within 3&#xD;
             months of study entry.&#xD;
&#xD;
          -  Alcohol abuse or drug abuse.&#xD;
&#xD;
          -  Clinically relevant cardiovascular, gastrointestinal, hepatic, neurological,&#xD;
             endocrine, hematological or psychiatric illness, other serious illnesses, uncontrolled&#xD;
             medical conditions or active infections making implementation of the protocol&#xD;
             difficult.&#xD;
&#xD;
          -  Medical, psychiatric, or neurologic condition that renders the patient unable to&#xD;
             understand the nature and scope of the study. Mental retardation or language barrier&#xD;
             such that the patient is unable to give informed consent.&#xD;
&#xD;
          -  Participation in an investigational trial within 30 days of study entry.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mosaad I Morsi, MBBCH, MSC</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>September 6, 2007</study_first_submitted>
  <study_first_submitted_qc>September 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>September 10, 2010</last_update_submitted>
  <last_update_submitted_qc>September 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin glulisine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

